Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib

Authors
Category Primary study
JournalHaematologica
Year 2012
This article has no abstract
Epistemonikos ID: 404688e2a3a2128bf766c3a5a788c4d76dad225c
First added on: Feb 06, 2025